Eco Polymer
Series B in 2025 
Eco Polymer focuses on research and production of medical catheters and membrane materials for various applications in the medical device industry.
Stairway Medical
Series B in 2025 
Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.
Auron Therapeutics
Series B in 2025 
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.
Baoling Bio
Series B in 2025 
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.
Xinzeyuan
Series B in 2025 
Xinzeyuan Medical specializes in the manufacturing of critical precision components and disposable medical endoscopes, serving primarily hospital clients. Their product portfolio includes minimally invasive surgical instruments and other medical consumables, aiming to enhance safety and efficiency in surgical procedures for healthcare professionals.
Leyden Labs
Series B in 2025 
Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.
AusperBio
Series B in 2024 
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.
The goal of Stepstar is to "Ten Times the Possibility of Everyone" through Intelligent Step. Step Star firmly creates its own super model and actively uses important resources like
Soda Health
Series B in 2024 
Founded in 2021, Soda Health is a Chicago-based healthcare technology company committed to reducing health disparities by addressing social determinants of health. It operates a platform that delivers personalized benefits, providing real-time access to essential services such as healthy food, over-the-counter medications, and transportation.
XellSmart
Series B in 2024 
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
Tachem is a biotechnology company that develops, produces, and distributes a range of products derived from the protected amino acid series. These products cater to diverse industries, including medical, healthcare, food, and cosmetics, among others. Tachem's primary offerings comprise protective amino acids, non-natural amino acids, and high-quality chemical raw materials, serving as biotechnical solutions for various industrial users.
Hope Medicine
Series B in 2024 
Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.
LongBio Pharma
Series B in 2024 
LongBio Pharma is a biotechnology company focused on developing antibody-based biologics for autoimmune and allergic diseases. Its platform concentrates on complement and IgE pathways, aiming to provide affordable, high-quality treatments that enhance patients' access to more effective therapies.
Mufan Power
Series B in 2024 
Mufan Power is a new energy high-tech enterprise specializing in turbomachinery. It develops a new generation of zero-carbon hydrogen power generation technologies and products, with hydrogen gas turbines as its core offering. These turbines are intended for distributed energy and data centers, rail transit, ship power, vehicle power, and energy storage peak shaving, supporting carbon-neutral applications across multiple sectors.
SPEEDIANCE
Series B in 2024 
Speediance designs and operates smart at-home fitness equipment for strength training and provides an online platform with training guidance and strength-training courses, connecting individual users with a workout community and resources to improve home workouts.
Pelliot is an outdoor sports brand that designs and manufactures high-performance clothing for outdoor enthusiasts. The company specializes in innovative design and research & development, offering a range of products including performance, mountain, classic, and training wear. Pelliot's commitment lies in producing professional-grade outdoor sports products, supporting outdoor lovers with reliable equipment.
Outpace Bio
Series B in 2024 
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Founded in 2018, Engitist specializes in researching, manufacturing, and selling high-precision optical measurement and testing equipment for the semiconductor industry. Based in Suzhou, China, the company offers products such as microscopic film measurement, optical defect detection, and optical linewidth measurement equipment, serving customers globally.
Alpha Biopharma
Series B in 2024 
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor designed to treat patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) who have central nervous system metastases. Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consulting and management team to ensure rigorous research and development processes. The company emphasizes a multi-faceted approach to drug development, which includes research, market strategy, and intellectual property protection, while working closely with leading contract research organizations, contract manufacturing organizations, hospitals, and institutes to facilitate the orderly implementation of its projects.
Novamab is a biotechnology company specializing in the development of novel nanobodies, a type of single-domain antibody with unique therapeutic advantages. With over 15 years of experience in nanobody research and development, the company's team of pioneers in this field has established platforms to maximize the potential of nanobodies. Novamab focuses on creating innovative drug formulations such as inhaled macromolecular drugs, albumin nanobody long-acting therapies, and nanobody double-antibody combinations. Their primary goal is to address unmet clinical needs by improving administration methods and reducing treatment cycles for major chronic diseases like cancer, autoimmune disorders, and cardiovascular conditions.
CureGenetics
Series B in 2024 
CureGenetics is a biotechnology company focused on advancing innovative medicines and molecular diagnostics through the application of gene editing technologies. The company specializes in the research and development of solutions aimed at the treatment of cancers and genetic diseases. CureGenetics is dedicated to creating next-generation therapies that enhance patient outcomes by leveraging cutting-edge techniques in gene editing and delivery platforms. Through its efforts, the company aims to contribute significantly to the field of personalized medicine and improve treatment options for complex health conditions.
Zhipu AI is a technology company specializing in developing large-scale artificial intelligence models. It offers API services powered by its General Language Model (GLM) series, designed to handle both Chinese and English tasks. The company's products include chatbots and advanced AI tools, aiming to reduce manual labor in digital tasks.
Hope Medicine
Series B in 2024 
Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.
Ruining Bio
Series B in 2024 
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.
DeBank offers a cryptocurrency wallet that enables users to track their decentralized finance (DeFi) investments across multiple blockchains. It supports over 800 DeFi protocols, allowing users to monitor deposits, earned interest, and perform token swaps.
ABUP specializes in over-the-air (OTA) technology solutions for the automotive and Internet of Things (IoT) sectors. The company delivers a range of products that include firmware upgrades, software upgrades, and cloud diagnosis services tailored for vehicles and IoT devices. By leveraging artificial intelligence and big data, ABUP enables its clients to enhance their offerings, ensuring that products remain current and provide users with a customized experience. The company's solutions are designed to support original equipment manufacturers (OEMs) in managing OTA systems effectively, facilitating continuous innovation and personalized service within the rapidly evolving landscape of connected technologies.
Saints & Sages
Series B in 2023 
Saints & Sages Medical specializes in the development and production of minimally invasive surgical medical devices. The company offers a range of energy devices that are utilized across various medical fields, including hepatobiliary, gynecology, urology, thoracic surgery, thyroid and breast surgery, and gastrointestinal surgery. With a commitment to addressing clinical needs, Saints & Sages focuses on innovation in surgical technology. They leverage a dedicated research and development team and extensive clinical experience to create devices that enhance the precision and efficiency of surgical procedures, ultimately aiming to improve patient outcomes globally.
Solo Music
Series B in 2023 
Solo Music is an AI-based music education platform that provides online education services for several musical instruments.
Zhipu AI is a technology company specializing in developing large-scale artificial intelligence models. It offers API services powered by its General Language Model (GLM) series, designed to handle both Chinese and English tasks. The company's products include chatbots and advanced AI tools, aiming to reduce manual labor in digital tasks.
Cornerstone Robotics
Series B in 2023 
Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.
CuroVax, established in 2011 and headquartered in Changzhou City, China, specializes in vaccine development and production. The company offers a range of vaccines, including a freeze-dried rabies vaccine for human use and an influenza virus split vaccine. CuroVax employs a dual approach of independent development and collaborative research, supported by multiple technology platforms such as large-scale mammalian cell culture and mRNA vaccine development. It provides biotechnology and microbiology services, focusing on improving health and medical industry standards.
Abdera Therapeutics
Series B in 2023 
Abdera is an oncology company developing targeted alpha therapies for patients with relapsed, refractory, or metastatic cancers. Its precision oncology platform integrates drug development and antibody engineering technologies to create novel radiopharmaceuticals that specifically target tumors while minimizing systemic toxicities.
1 Yong Cloud
Series B in 2023 
1 Yong Cloud is a Beijing-based company founded in 2017 that specializes in developing and operating a tumor diagnosis and treatment standardization platform. The platform is designed to assist healthcare professionals in formulating personalized diagnosis and treatment plans for patients with tumor diseases. By collecting and translating medical data, 1 Yong Cloud aims to enhance the quality and standardization of medical practices while rationalizing treatment expenses. Through its comprehensive data and system services, the company supports physicians in making informed decisions to improve patient outcomes.
Allorion Therapeutics
Series B in 2023 
Allorion Therapeutics is a biopharmaceutical company specializing in the development of small molecule therapeutics for cancer and autoimmune diseases. Headquartered in Natick, Massachusetts, with operations in Guangzhou, China, Allorion focuses on innovative drug designs to enhance efficacy and mitigate patient resistance.
Jiangsu Jing Chuang Advanced Electronic Technology
Series B in 2023 
Jiangsu Jing Chuang Advanced Electronic Technology focuses on the research and development of equipment for the semiconductor manufacturing sector. The company specializes in high-precision grinding machines and offers a range of products, including automatic laser saws, dicing saws, and wafer cleaning equipment. By providing comprehensive solutions for semiconductor material dicing applications, Jing Chuang Advanced aims to support the growing demands of the semiconductor industry.
Vongi offers medical solution design, product design and RandD, pilot test transformation, clinical research, registration services, and commercial operations for companies that need digital therapy, real-world research, and digital therapy CDMO and process services. For inquiries, their email address, telephone number, and physical address are available on their website.
OriCell Therapeutics
Series B in 2023 
OriCell Therapeutics is a biopharmaceutical company that specializes in the development of innovative cellular drugs aimed at addressing unmet clinical needs in tumor immunotherapy. The company focuses on creating therapeutics for a range of cancers, including liver cancer, myeloma, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. With a commitment to effective and affordable treatment options, OriCell Therapeutics aims to enhance patient care through the development of clinically valuable therapies, seeking to establish itself as a leader in the field of novel oncological treatments.
Hochuen Medical
Series B in 2023 
Hochuen Medical USA Corp., established in 2015 by industry veterans Dr. Robin Liu and Eric Zeng, specializes in the design, development, and mass production of medical devices and consumables as an Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM). The company focuses on In Vitro Diagnostics (IVD), wearable medical technology, and microfluidic devices, with a portfolio including COVID-19 testing kits and various medical disposables. Hochuen Medical operates as a Contract Development and Manufacturing Organization (CDMO), producing high-quality products such as microfluidic biochips, IVD disposable consumables, point-of-care testing kits, and gene sequencing chips for clients worldwide. The company is committed to quality, holding FDA registration and ISO certifications, and aims to contribute innovative solutions to the healthcare industry through continuous research and development.
Tingsheng Technology
Series B in 2023 
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
Yike Polymers
Series B in 2023 
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Singular Medical
Series B in 2023 
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.
Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.
Fitlens is a company that provides ophthalmic medical treatment. They specialize in the design and manufacture of high-end, complicated optical contact lenses as well as the design and manufacture of high-end intraocular lens optical molds.
Core Medical
Series B in 2022 
Core Medical (Beijing) Co., Ltd. is a contract research organization (CRO) founded in 2013 and based in Beijing, China. The company specializes in clinical professional services focused on new technologies and innovative products within the cardiovascular sector. Core Medical offers a range of services, including animal testing, type testing, First-in-Man (FIM) studies, human studies, and statistics and data management for clinical research. By providing these services, Core Medical helps companies in the cardiovascular field evaluate and validate their products, facilitating advancements in medical technology.
Focallure
Series B in 2022 
Focallure is a cosmetic company headquartered in Guangzhou, China, specializing in the development and manufacturing of makeup products. The company emphasizes base makeup and a variety of cosmetics, utilizing big data analysis to enhance its operations. By analyzing consumer product preferences and social content trends, Focallure aims to provide users with an innovative and refreshing makeup experience.
iMile specializes in logistics and courier services across the Middle East. It caters primarily to e-commerce businesses, offering innovative solutions such as Cash on Delivery with tracking, real-time online tracking, international transport, overseas warehousing, and last-mile delivery.
Scroll.io
Series B in 2022 
Scroll, founded in 2021 and based in Victoria, Seychelles, is focused on developing an EVM-equivalent zk-rollup, which utilizes a robust proving network. The company operates within the technology sector, with an emphasis on enhancing blockchain scalability and efficiency. By leveraging zero-knowledge proof technology, Scroll aims to facilitate faster and more secure transactions on decentralized applications. The firm's innovative approach positions it as a key player in the evolving landscape of blockchain infrastructure.
OriginCell
Series B in 2022 
Shanghai Origincell Biological Cryo Equipment Co., Ltd. is a biomedical enterprise established in 2014, headquartered in Shanghai, China. The company specializes in immunological cell collection, separation, and storage services. It manufactures biobanking storage devices, including cryogenic freezers and biobank systems. In addition to its storage solutions, Origincell develops tumor immunotherapy solutions, utilizing advanced technologies such as the 10-phage display library and humanized antibody technology. These innovations support medical facilities in their cancer treatment efforts, positioning Origincell as a key player in the intersection of biobanking and cancer therapy.
Norm Medtech
Series B in 2022 
Norm Medtech focuses on developing interventional medical devices. 
Norm Medtech is headquartered in  Zhejiang, China.
Biren Technology
Series B in 2022 
Biren Technology is a high-tech startup specializing in the design and development of intelligent processors tailored for GPU and DSA computation architectures. The company focuses on creating integrated software and hardware platforms that support intelligent computing applications, including cloud computing, artificial intelligence training, graphics rendering, and high-performance general-purpose computing. With a dedicated team of industry experts and elite engineers, Biren Technology aims to deliver versatile computing solutions that blend general computing capabilities with specific applications. Its research division is committed to advancing key technologies in intelligent computing systems, emphasizing new architectures and advanced compilation techniques, thereby facilitating technological breakthroughs in various high-tech sectors.
GYENNO Technologies
Series B in 2022 
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.
OriCell Therapeutics
Series B in 2022 
OriCell Therapeutics is a biopharmaceutical company that specializes in the development of innovative cellular drugs aimed at addressing unmet clinical needs in tumor immunotherapy. The company focuses on creating therapeutics for a range of cancers, including liver cancer, myeloma, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. With a commitment to effective and affordable treatment options, OriCell Therapeutics aims to enhance patient care through the development of clinically valuable therapies, seeking to establish itself as a leader in the field of novel oncological treatments.
Chatail is a company that specializes in developing sales software tailored for live commerce. It provides a comprehensive live broadcast sales mechanism for businesses, facilitating the effective use of live video to enhance sales efforts. The platform is designed to help brands initiate and optimize their live video commerce strategies, allowing sales associates and call center representatives to engage customers interactively and drive traffic to physical retail locations. Key features of Chatail's offerings include cross-store linking, enterprise micro synergy, and various sales tools that enhance the overall sales process without requiring live broadcasts. Through its innovative approach, Chatail aims to transform the way businesses leverage live video for sales growth.
Qingflow is a software-as-a-service platform based in Minhang District, Shanghai, that specializes in business workflow management solutions. The company offers a customizable platform that allows users to design and combine various modules to create personalized management systems tailored to their specific needs. This user-friendly approach enables individuals and organizations to build their own business management systems without requiring any programming skills, making it accessible for a wide range of users seeking to enhance their operational efficiency.
Gaugene is a high-tech enterprise that specializes in the development and supply of hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. The company offers advanced instruments and reagents that play a critical role in hematology diagnosis, as well as broader clinical diagnostics and life science research. Gaugene is notable for being the only manufacturer in China that incorporates high-power flow lasers and high-sensitivity multi-color fluorescence detection systems in its products. This technological edge enables the company to provide innovative solutions for clinical diagnosis, flow cytometry technology, single cell research, protein screening, and the discovery of new clinical indicators. Gaugene is co-sponsored by experienced professionals from renowned domestic IVD companies, ensuring a strong foundation in industry-leading technologies.
RiboX Therapeutics
Series B in 2022 
RiboX Therapeutics is a biotech company that focuses on discovery and development of fully engineered circular RNA therapeutics.
Cubenergy Technology
Series B in 2022 
Cubenergy Technology is an energy technology company specializing in energy data operation services and the integration of distributed energy storage systems. The company develops advanced energy management and storage systems that utilize data analysis to optimize performance and maintain system efficiency. By providing innovative solutions in energy management, Cubenergy Technology aims to enhance the operation of energy storage systems, ensuring that users achieve optimal control and performance in their energy applications.
LaNova Medicines
Series B in 2022 
LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.
Boulder Care
Series B in 2022 
Boulder Care, established in 2017 and headquartered in Portland, Oregon, specializes in telemedicine-based programs for opioid addiction treatment. The company offers comprehensive services including medication-assisted treatment with buprenorphine, peer support, patient counseling, and psychosocial services to aid recovery. Boulder Care serves patients directly, as well as healthcare providers and organizations seeking to expand access to effective opioid addiction treatment.
Founded in 2019 by former Snap engineers, BUD is a Singapore-based company building an open metaverse gaming platform. It connects millions of user-generated virtual worlds created by its community of creators. Since its launch in November 2021, BUD has become a top social app in over 38 countries, facilitating the creation and trade of millions of 3D content.
Point One
Series B in 2022 
Point One is a 3D Metaverse user-generated content platform. Using simple no-code tools, users may build personalized 3D interactive content.
Yike Polymers
Series B in 2022 
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Ashermed is a provider of contract research organization (CRO) services specifically designed for medical companies. The company emphasizes the integration of advanced technologies, such as Internet technology, big data, and artificial intelligence, to enhance the drug development process. By leveraging these technologies, Ashermed aims to shorten the clinical data development cycle and improve the quality of research outcomes, ultimately reducing research and development costs for its clients. Their offerings include CRO services, site management organization (SMO) support, patient recruitment, and digital platform assistance, all tailored to facilitate the needs of the medical industry.
Onechip Bioelectronics
Series B in 2022 
Wanzhong Yixin Biotechnology is a developer of semiconductor integrated circuit biosensor chips and other related devices. The company's biosensor chip products are used in emerging fields such as genetic testing, water quality monitoring, and environmental protection IoT monitoring.
Vistel is a technology company established in 2016 by Sun Yuhui and Ding Dayong, specializing in artificial intelligence applications within the medical field. The firm develops AI-driven ophthalmic medical imaging technology designed to enhance the diagnosis of eye diseases. By employing advanced diagnostic systems that utilize computer vision processing and sophisticated image annotation, Vistel aims to provide medical practitioners with the tools necessary to digitally analyze and manage patients' ocular conditions effectively.
Curie.Bio
Series B in 2022 
Curie.Bio is a Boston-based venture capital firm founded in 2022 that focuses on founder-led seed-stage investments in therapeutics companies.
MeetFuture
Series B in 2022 
MeetFuture China is a technology-driven company specializing in automated transmission systems for the pan-semiconductor industry. Established in 2016, it offers innovative automation solutions aimed at enhancing industrial upgrading and development. The company leverages control theory, computer technology, and information systems to deliver effective industrial detection, control, optimization, dispatch, and management solutions. By implementing these advanced technologies, MeetFuture enables its clients to reduce operational costs and optimize production parameters, thereby improving overall efficiency and productivity in the semiconductor sector.
MediLink Therapeutics
Series B in 2022 
MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.
HashQuark
Series B in 2022 
HashQuark is a provider of staking and blockchain infrastructure services, specializing in ecosystems built on Proof of Stake (PoS) and Delegated Proof of Stake (DPoS) technologies. Founded in 2018 and headquartered in Grand Cayman, Cayman Islands, the company delivers a range of services, including staking solutions for individuals, institutions, and market professionals. Its Staking Cloud platform enables token holders to securely store their tokens while earning staking rewards, catering to both retail and institutional investors. HashQuark has achieved global server deployment, ensuring support for all major PoS blockchains, and emphasizes security, stability, and convenience in its offerings.
Zhipu AI is a technology company specializing in developing large-scale artificial intelligence models. It offers API services powered by its General Language Model (GLM) series, designed to handle both Chinese and English tasks. The company's products include chatbots and advanced AI tools, aiming to reduce manual labor in digital tasks.
Deep View Technology
Series B in 2022 
Deep View Technology specializes in motion capture and augmented reality (AR) and virtual reality (VR) applications. The company focuses on research and development in three-dimensional computer vision algorithms, utilizing wearable devices to identify and capture human gestures and postures in real time. This innovative approach enables clients to enhance their VR experiences by accurately translating physical movements into digital environments, thus facilitating a more immersive interaction with technology.
CureGenetics
Series B in 2022 
CureGenetics is a biotechnology company focused on advancing innovative medicines and molecular diagnostics through the application of gene editing technologies. The company specializes in the research and development of solutions aimed at the treatment of cancers and genetic diseases. CureGenetics is dedicated to creating next-generation therapies that enhance patient outcomes by leveraging cutting-edge techniques in gene editing and delivery platforms. Through its efforts, the company aims to contribute significantly to the field of personalized medicine and improve treatment options for complex health conditions.
Korro Bio
Series B in 2022 
Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.
Tungee, founded in 2016, specializes in providing intelligent sales solutions for B2B enterprises. By leveraging artificial intelligence and big data, the company has developed a comprehensive sales forecasting platform that encompasses various functions, including lead mining, business opportunity engagement, customer relationship management, and order analysis. Tungee's innovative approach addresses the challenges faced by businesses in identifying, contacting, and managing customers, leading to more efficient acquisition of accurate sales leads and reduced customer acquisition costs. As a leader in the Chinese intelligent sales sector, Tungee has successfully served over 3,000 enterprise clients, including prominent organizations such as Alibaba and China Mobile.
WoXiaoYa is a food and beverage brand that makes and sells chidren's nutritional supplement products.
InfStones
Series B in 2021 
InfStones, founded in 2018, operates as a prominent blockchain infrastructure provider with offices in three countries across two continents. The company specializes in offering services to large institutional clients worldwide, facilitating the management of thousands of nodes on over 50 public blockchains through its universal platform. Additionally, InfStones has developed a decentralized cloud storage solution that allows institutions to securely establish and host their mainnet. This platform is designed to simplify the process of connecting with blockchain technology, enabling clients to efficiently develop and deploy their applications on various blockchain networks.
DP Technology
Series B in 2021 
DPTechnology, founded in 2018 and based in Beijing, China, specializes in micro-scale industrial design through advanced molecular simulation technology. The company has developed a platform that integrates artificial intelligence with molecular simulation algorithms, aiming to enhance industrial and medical research. By providing users with innovative scientific tools, DPTechnology promotes efficiency and creativity in exploring complex research challenges, thereby establishing a new paradigm in both industrial research and clinical applications.
Wholee is an e-commerce website, dedicated to become customers' reliable lifetime partners.
Cornerstone Robotics
Series B in 2021 
Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.
Platelet BioGenesis
Series B in 2021 
Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2014. It specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical applications. The company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing essential therapeutic resources to patients globally. Through its innovative approach, Platelet BioGenesis is contributing to advancements in biotechnology and the field of transfusion medicine.
Okeanos Technology
Series B in 2021 
Okeanos Technology specializes in the custom synthesis and production of specialized chemical biological reagents and pharmaceutical intermediates tailored for the life sciences sector. The company offers a diverse range of products, including modified nucleotides, unnatural amino acids, heterocycles, as well as fluorescent and labeling reagents. Okeanos serves prominent pharmaceutical companies, delivering high-quality chemical compounds and intermediates that support various applications in research and development. Renowned for its commitment to quality and innovation, Okeanos has established a strong reputation among its clients in the pharmaceutical industry.
GenLight Medical
Series B in 2021 
GenLight Medical is a company based in Hangzhou, China, that specializes in developing innovative treatment solutions for epilepsy and other neurological disorders. The firm focuses on creating advanced laser medical equipment and technologies aimed at improving patient outcomes in the fields of brain science and neurosurgery. Among its notable advancements are brain-computer control technology, full-cranial implantation techniques for deep brain nerve stimulation, brain computer chips, and systems for magnetic resonance guided laser ablation, which facilitate minimally invasive surgical procedures. GenLight Medical is committed to providing high-end, technologically advanced solutions for patients requiring brain surgery.
Structure Therapeutics
Series B in 2021 
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.
Qingflow is a software-as-a-service platform based in Minhang District, Shanghai, that specializes in business workflow management solutions. The company offers a customizable platform that allows users to design and combine various modules to create personalized management systems tailored to their specific needs. This user-friendly approach enables individuals and organizations to build their own business management systems without requiring any programming skills, making it accessible for a wide range of users seeking to enhance their operational efficiency.
Sunyur is an intelligent technology company that specializes in providing digital procurement solutions tailored for large and medium-sized businesses. The company develops an intelligent procurement platform and offers software as a service (SaaS) applications, enabling clients to create customized online procurement systems. By digitizing and enhancing the procurement processes, Sunyur helps enterprises streamline operations, improve efficiency, and reduce costs. Through its innovative solutions, the company supports clients in establishing exclusive digital procurement platforms that facilitate smarter and more efficient purchasing practices.
Ventyx Biosciences
Series B in 2021 
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.
Alamar Biosciences
Series B in 2021 
Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.
Rox Motor
Series B in 2021 
ROX Motor is a company dedicated to the development of off-road new energy vehicles, specializing in innovative technologies that enhance smart car capabilities. The firm focuses on research and development in several key areas, including new energy power systems, intelligent cockpit designs, and autonomous driving solutions. By providing advanced product definitions and core intelligence technologies, ROX Motor aims to improve the overall quality of products within the new energy vehicle industry, catering to the growing demand for environmentally friendly and technologically advanced transportation options.
GYENNO Technologies
Series B in 2021 
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.
moodytiger
Series B in 2021 
moodytiger is a technical athletic apparel brand for children from age of 4 to 16. Today, kids from more than 100 countries, from United States to Australia, from Singapore to Hong Kong, have worn moodytiger outfits in their wonderful active adventure! 
Born to redefine kids’ athlectic wear from day one, our products are specially tailored for children with perfect combination of high-tech fabrics and fashion-forward designs, and functionally suited for multiple sports, including tennis, skiing, skating, swimming, outdoor, and everyday active living. As one of the fastest growing and most innovative brands in the category, we thrive to be the new industry benchmark setter with what we do.
Lingyi Zhihui
Series B in 2021 
Zuoshouyisheng's AI doctor platform spans 35 medical specialties and can diagnose more than 6,000 diseases, according to the company’s website. Zuoshouyisheng mainly collaborates with customers through a SaaS business model, providing its AI-empowered healthcare system to hospitals, pharmaceutical companies, employers, and insurers.
Berry Oncology
Series B in 2021 
Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.
Zion Pharma
Series B in 2021 
Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.
Kingsware
Series B in 2021 
Kingsware is a developer of robotic process automation (RPA) software aimed at enhancing operational efficiency for businesses in various sectors, including finance and production. The company specializes in creating an enterprise-level robot management platform that emphasizes safety, ease of use, and robust performance. Its RPA system automates repetitive tasks and business operations, allowing enterprises to streamline processes in production, finance, and supply chain management. Kingsware's solutions are designed for deployment in large-scale, highly integrated environments, ensuring stability and efficiency across complex organizational frameworks.
Health Biotech
Series B in 2021 
Health Biotech is a research and development firm focused on precision medicine through the application of mass spectrometry technology. The company specializes in creating comprehensive detection solutions that include tools, equipment, and reagent consumables. Its innovative technology employs liquid chromatography-mass spectrometry to facilitate the early diagnosis, treatment, and monitoring of Alzheimer's disease. By quantitatively detecting specific biomarkers, such as "ipilin," Health Biotech enables healthcare professionals to assess Alzheimer's risk and provide targeted interventions aimed at delaying disease onset and enhancing cognitive function in patients. Through its commitment to advancing mass spectrometry applications, Health Biotech strives to deliver reliable services and improve patient outcomes in the realm of neurological health.
Hope Medicine
Series B in 2021 
Hope Medicine is a biopharmaceutical company focused on researching, developing, and commercializing innovative drugs to enhance the quality of life for various common male and female diseases. The company specializes in translational medicine and aims to address significant health challenges by leveraging global research initiatives. Hope Medicine is engaged in the development of monoclonal antibodies, protein-based therapies, and other drug formulations targeting endocrine, cardiovascular, and metabolic diseases. Through its efforts, the company seeks to provide underserved patient populations with access to effective and affordable treatments, ultimately improving their health outcomes.
Just Medical
Series B in 2021 
Just Medical is a developer and manufacturer of artificial orthopedic implant devices and systems, specializing in products such as artificial hip and knee joints, internal fixation products, and orthopedic surgical instruments. The company is dedicated to enhancing surgical efficiency and improving the quality of orthopedic treatment through advanced technology research and development. Just Medical focuses on creating safe and effective medical products and services, continually refining its product system to address the needs of healthcare providers and alleviate patient pain. Its commitment to high-speed development and excellence positions it as a key player in the orthopedic medical device industry.
Valgen Medtech
Series B in 2021 
Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.
Tasogare Coffee is a premium coffee brand located in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, ensuring accessibility for its customers. With a commitment to quality, Tasogare Coffee aims to deliver an exceptional coffee experience, appealing to discerning coffee enthusiasts.